Xentuzumab
Based on 1 publication(s) in Google Scholar
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.71%
- CAS 番号: 1417158-65-6
- 分子量:143.7 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Xentuzumab
More
生物活性
Human IgG1 lambda2
Human
IGF-1 & IGF-2
Xentuzumab (0.01-1 mM; 96 h) inhibits IGF type 1 receptor signaling and (0.1 μM; 48 h) AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cell in a dose-dependent manner[1].
Xentuzumab (0.01-1 mM; 5-10 d) losses of antiproliferative activity against PTEN-null LNCaP or PC-3 cells when PTEN knockdown[1].
Xentuzumab (1 μM; 24-72 h) arrests cell cycle at sub-G1 phase and induces apoptosis in VCaP cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Prostate cancer VCaP cells
-
Concentration:0.1 μM
-
Incubation Time:24 h and 48 h
-
Result:Increased in cleaved caspase 3/7 and PARP.
Decreased the level of phosphorylation of FoxO3a (S253)/FoxO1 (T24).
-
Cell Line:Prostate cancer VCaP cells
-
Concentration:1 μM
-
Incubation Time:24 h, 48 h, and 72 h
-
Result:Increased in cleaved caspase 3/7 and induces cell apoptosis.
Increased the sub-G1 cell population.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)[1]
-
Dosage:200 mg/kg
-
Administration:Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose
-
Result:Resulted in significant reductions in tumor volume.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
-
Immobilized Human IGF-I Protein, His Tag can bind Xentuzumab. The EC50 for this effect is 9.81 ng/mL.
化学情報
-
CAS 番号 1417158-65-6
-
性状 Liquid
-
分子量 143.7 kDa
-
Color Colorless to light yellow
-
SMILES
[Xentuzumab]
-
別名
BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma. [Abstract]2024 Jun 10;42(6):1067-1085.e11. PMID: 38759655
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Xentuzumab 関連分類
HY-P99274 関連分類
Powered by Bioz